Research Article

No association between low-dose reserpine use and depression in older hypertensive patient: result of a multicenter, cross-sectional study

Guo-Hua ZHU1, Xi-Peng SUN1, Jing LI1, Lin PI2, Hai-Qin TANG3, Hai-Qing GAO4, Hong-Liang CONG5, Peng QU6, Xin-Zheng LU7, Xin-Jun ZHANG8, Luo-Sha ZHAO9, Yi-Fang GUO10, Dong-Xia LIU11, Liang-Qing ZHANG12, Hua TANG1, Yi-Xin HU13, Li FAN13,#, Qi HUA1,#

1Department of Cardiology, Xuanwu Hospital Capital Medical University, Beijing, China
2Department of Cardiology, Chuiyangliu Hospital affiliated to Tsinghua University, Beijing, China
3Department of Cardiology, the First Affiliated Hospital of Anhui Medical University, Hefei, China
4Department of Cardiology, Tianjin Chest Hospital, Tianjin, China
5Department of Cardiology, the Second Hospital of Dalian Medical University, Dalian, China
6Department of Cardiology, Jiangsu Provincial Hospital, Nanjing, China
7Department of Geriatrics, West China Hospital, Sichuan University, Chengdu, China
8Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
9Department of Geriatrics, Hebei General Hospital, Shijiazhuang, China
10Department of Cardiology, Shanshui Cardiovascular Hospital, Xian, China
11Department of Cardiology, Shanxi Cardiovascular Hospital, Xian, China
12Department of Geriatrics, Chinese PLA General Hospital, Beijing, China

Abstract

Background  Reserpine is currently used by millions of Chinese hypertensive patients, in spite of the continued concern of its depressive effect, even when used in low dose. This study aimed to investigate the association between low-dose reserpine use and depression in older Chinese hypertensive patient. Methods  In this cross-sectional, case-control study, we recruited patient aged 60 years or over who had regularly taken one or two tablets of "compound reserpine and triamterene tablets (CRTTs)" for more than one year (reserpine user) from 26 community health centers located in 10 provinces in China. For each patient who took CRTTs, we selected an age (within five years) and sex matched hypertensive patient who had never taken any drugs containing reserpine (non-reserpine user) as control. Depressive symptoms were evaluated using a Chinese depression scale adapted from the Zung Self-Rating Depression Scale. Demographic, clinical data and laboratory examination results within six months were collected. Results  From August 2018 to December 2018, 787 reserpine user and 787 non-reserpine user were recruited. The mean age of all study subjects was 70.3 years, with about equal numbers of males and females. The mean depression score was 40.4 in reserpine users and 40.6 in non-reserpine users (P = 0.7). The majority of study subject had a depression score < 53 (87.6% in reserpine users and 88.2% in non-reserpine users, respectively). There were no significant differences in the prevalence of mild, moderate or severe depression in reserpine users and non-reserpine users. Conclusions  There is no association between low-dose reserpine use and depression in older hypertensive patient. The role of reserpine in the treatment and control of hypertension should be reconsidered; and further studies, especially randomized, controlled clinical trials to compare efficacy and safety of reserpine and other widely recommended anti-hypertensive agents are needed.

Clinical Trial Number: ChiCTR1800017684

J Geriatr Cardiol 2019; 16: 608–613. doi:10.11909/j.issn.1671-5411.2019.08.001

Keywords: Depression; Hypertension; Reserpine

*Correspondence to: Li FAN, Department of Geriatrics, Chinese PLA General Hospital, Beijing, China; Qi HUA, Department of Cardiology, Xuanwu Hospital Capital Medical University, Beijing, China. E-mails: fl6698@163.com (FAN L); huaqi5371@sina.com (HUA Q)

Received: July 24, 2019  Revised: August 21, 2019
Accepted: August 24, 2019  Published online: August 28, 2019

http://www.jgc301.com; jgc@jgc301.com | Journal of Geriatric Cardiology
1 Introduction

Reserpine, an alkaloid extracted from the root of Rauwolfia serpentina which was introduced to modern medicine in the mid-1940s, was one of the earliest drugs used to treat hypertension.[1] Reserpine binds to the storage vesicles in adrenergic neurons and inhibits the uptake of norepinephrine and dopamine, which leads to their degradation by cytoplasmic monoamine oxidase, and thus reduces cardiac output and peripheral resistance.[1]

Randomized, placebo-controlled clinical trials conducted in western countries from 1960s to 1990s had continuously demonstrated the powerful blood pressure (BP) lowering effect of reserpine, when combined with thiazide diuretics and hydralazine,[2,3] or combined with thiazide diuretics alone.[4-7] More recently, reserpine was included as one of the optional step 2 agents in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.[8] At five years, reserpine was used by 4.3% of subjects and showed similar, or perhaps better results in reducing BP and cardiovascular events, when compared with atenolol or clopidogrel.[8]

Despite the dramatic decrease to near demise of reserpine use since the 1980s in westernized countries, partly attributed to several adverse effects of reserpine reported in studies conducted in the 1950s to 1970s, which included depression, gastric bleeding, and breast cancer.[9] In China, however, reserpine is still used extensively in the treatment of hypertension, usually at low dose and as an ingredient in fixed-dose compounds. Recent local and nation-wide surveys indicate that about 5 millions to 20 millions of Chinese patients with hypertension are using reserpine as one of the treatment medications.[10-12]

In the Hypertension Detection and Follow-Up Program, 1036 of patients were treated with reserpine. Authors of this study concluded that there was no evidence that reserpine cause breast cancer;[13] another large-size study with low-dose reserpine showed no increase of gastric bleeding.[14] Concern of the association of depression and reserpine use, however, is continued.[15] Therefore, we performed this multicenter, cross-sectional study to investigate the association between low-dose reserpine use and depression in elderly Chinese hypertensive patient.

2 Methods

2.1 Study subjects

This cross-sectional, case-control study was conducted from August 2018 to December 2018. We invited 26 community health centers (CHC) located in 10 provinces in China, including Beijing, Tianjin, Henan, Anhui, Shandong, Shanxi, Sichuan, Liaoning, Jiangsu and Hebei, to participate in this study. The Ethics Committee of Xuanwu Hospital Capital Medical University approved the study protocol (Clinical Trial Number: ChiCTR1800017684). All subjects provided written informed consent.

The most widely used fixed-dose compound containing reserpine for the treatment of hypertension in China is the “compound reserpine and triamterene tablets (here referred to by its acronym, CRTTs)”. Each table of CRTTs contains hydrochlorothiazide 12.5 mg, triamterene 12.5 mg, dihydralazine 12.5 mg and reserpine 0.1 mg. Previous study had confirmed the efficacy of this compound in treating hypertensive Chinese patients.[16] Thus, we recruited patient aged 60 years or over who had regularly taken one or two tables of CRTTs for more than one year in this study. For each patient who took CRTTs (reserpine user), we randomly selected from the same CHC an age (within five years) and sex matched hypertensive patient who had never been recruited drugs containing reserpine (non-reserpine user) as control. By the end of December 2018, 828 pairs of CRTTs patient and control had been recruited. We excluded 41 pairs with incomplete clinical data. Finally, 787 pairs of CRTTs patient and control were included in the analysis.

We assumed that patient at advanced age maybe more susceptible to the depressogenic effect of reserpine; thus, in this study, we also specifically compared the depression status reserpine user and non-reserpine user in those subjects aged 80 years or over.

2.2 Demographic and clinical data collection

Demographics and clinical data were gathered, including gender, age, height, weight, waist circumference, history of hypertension and other diseases, medication use, and laboratory examination results within six months, including concentrations of plasma sodium and potassium, serum creatinine and urea nitrogen, fasting blood glucose and plasma lipid profiles were collected.

2.3 Depressive symptoms assessment

Depressive symptoms were evaluated using a Chinese depression scale adapted from the Zung Self-Rating Depression Scale.[17] The Chinese depression scale used in our study has been validated previously.[18,19] This self-rating depression scale consists of 20 statements about feelings and symptoms of depression, such as sleep and appetite. Each statement is rated by the participant on a 4-point scale, ranging from a little of the time to most of the time. Total scores were multiplied by 1.25 to given a final scale ranging from 25 to 100, with higher scores indicating more depres-
sive symptoms. In this study, we used the following cutoffs for the classification of depression severity: < 53: no depression; 53–62: mild depression; 63–72: moderate depression; and ≥ 73: severe depression, according to Chinese norms.[20]

2.4 Statistical analysis

Statistical analyses were performed using SPSS 22.0 for Windows (IBM Corp., Armonk, NY, USA). Continuous data were presented as mean ± SD and compared using Student t test or Mann–Whitney U test. The categorical data were presented as percentage frequency (%) and compared using chi-squared test. A two-tailed P < 0.05 indicates statistical significance.

3 Results

3.1 Characteristics of patients with or without the use of reserpine

The demographic and clinical characteristics of patients who used CRTTs and those who did not use any reserpine-containing anti-hypertensive agents are shown in Table 1. The mean age of all study subjects was 70.3 years, with about equal numbers of males and females. There were no significant differences between reserpine users and non-reserpine users in duration of hypertension, systolic and diastolic blood pressure and laboratory variables. Compared to those non-reserpine users, patients who used CRTTs took less mean number of anti-hypertension medication tables per day (1.3 vs. 1.4, P = 0.021).

Table 1. Clinical characteristics of reserpine user and non-reserpine user.

|                         | Reserpine user (n = 787) | Non-reserpine user (n = 787) | P-value |
|-------------------------|--------------------------|------------------------------|---------|
| Age, yrs                | 70.4 ± 7.4               | 70.1 ± 6.9                   | 0.365   |
| Male/Female             | 392/395                  | 392/395                      | -       |
| BMI, kg/m²              | 25.5 ± 3.4               | 25.4 ± 3.6                   | 0.633   |
| Waist circumference, cm | 88.3 ± 10.6              | 88.0 ± 10.7                  | 0.614   |
| Duration of hypertension, yrs | 12.2 ± 9.8             | 11.5 ± 9.5                   | 0.158   |
| Type 2 diabetes         | 166 (22.0%)              | 189 (24.0%)                  | 0.165   |
| Coronary heart disease  | 219 (27.8%)              | 214 (27.2%)                  | 0.778   |
| Stroke                  | 129 (16.4%)              | 108 (13.7%)                  | 0.139   |
| Hypertension grade      |                          |                              | 0.467   |
| 1                       | 284 (36.1%)              | 294 (37.5%)                  |         |
| 2                       | 221 (28.1%)              | 234 (29.5%)                  |         |
| 3                       | 282 (35.8%)              | 259 (33.0%)                  |         |
| Systolic BP, mmHg       | 137.1 ± 16.1             | 138.7 ± 16.5                 | 0.057   |
| Diastolic BP, mmHg      | 80.3 ± 10.2              | 81.3 ± 10.8                  | 0.061   |
| Number of anti-hypertension medication table per day | 1.3 ± 0.6 | 1.4 ± 0.6 | 0.021 |
| Patient who use other anti-hypertension medication |                  |                              |         |
| CCB                     | 129 (16.4%)              | 552 (70.1%)                  | < 0.001 |
| ACEI                    | 32 (4.1%)                | 93 (11.8%)                   | < 0.001 |
| ARB                     | 75 (9.5%)                | 269 (34.2%)                  | < 0.001 |
| β blockers              | 34 (4.3%)                | 103 (13.1%)                  | < 0.001 |
| Diuretics               | 13 (1.7%)                | 54 (6.9%)                    | < 0.001 |
| Others                  | 7 (0.9%)                 | 3 (0.4%)                     | 0.204   |
| Serum creatinine, μmol/L| 78.9 ± 35.6              | 76.8 ± 30.6                  | 0.213   |
| Serum urea nitrogen, mmol/L | 6.1 ± 2.4             | 5.9 ± 1.9                    | 0.128   |
| Fasting glucose, mmol/L | 6.2 ± 1.9                | 6.3 ± 2.2                    | 0.204   |
| Triglycerides, mmol/L   | 1.8 ± 1.3                | 1.8 ± 1.3                    | 0.981   |
| Total cholesterol, mmol/L| 4.8 ± 1.2               | 4.9 ± 1.2                    | 0.171   |
| HDL-cholesterol, mmol/L | 1.4 ± 0.4                | 1.4 ± 0.4                    | 0.688   |
| LDL-cholesterol, mmol/L | 2.8 ± 0.9                | 2.8 ± 0.9                    | 0.307   |
| Potassium, mmol/L       | 4.2 ± 0.5                | 4.2 ± 0.5                    | 0.115   |
| Sodium, mmol/L          | 140.5 ± 8.9              | 140.6 ± 9.6                  | 0.909   |

Data are presented as means ± SD or n (%). ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; BMI: body mass index; CCB: calcium channel blocker; HDL: high-density lipoprotein; LDL: low-density lipoprotein.
3.2 Depressive symptoms in patients with or without the use of reserpine

The mean depression score was 40.4 in reserpine users and 40.6 in non-reserpine users \((P = 0.7)\). The majority of study subject had a depression score < 53 (87.6% in reserpine users and 88.2% in non-reserpine users, respectively). There were no significant differences in the prevalence of mild, moderate or severe depression in reserpine users and non-reserpine users (Table 2).

3.3 Depression status in patients 80 years or older

There were 102 subjects who were 80 years or older in reserpine users and 83 in non-reserpine users. There were no significant differences in either the mean depression score or the prevalence of mild, moderate or severe depression between the two sub-groups (Table 2).

4 Discussion

In this large scale, multicenter, cross-sectional study of elderly hypertensive patients, we found that compared with patients who took no reserpine, patients who had took low dose (0.1–0.2 mg/d) reserpine for one year or longer showed similar depressive symptom score and similar prevalence of mild, moderate or severe depression, while both systolic and diastolic BP were also similar between the two sub-groups.

To our knowledge, the only previous study specifically addressed the relationship between reserpine use and depression was reported by Lemieux and associates.[21] In their study, 195 patients took Rauwolfia products, of them 134 took reserpine alone, and 101 patients took no Rauwolfia products. Of the 101 patients in that study who took no Rauwolfia or reserpine, none reported developing depression. Of the group that took Rauwolfia products, 30 of 195 patients reported developing depression. The daily dosage of reserpine used in their studied patients was 0.75 to 4 mg, with an average of 1.36 mg, much larger than the dosage used in our studied subjects. Several later studies in which low dosages (0.05–0.1 mg/d) of reserpine are used showed that reserpine is well tolerated and that depression develops at rates similar to those seen in the general population.[16,22,23] Although the dose-related hypotensive effect of reserpine needs further investigation,[24] a randomized trial showed that doses of 0.125 mg and 0.05 mg produced 90% and 82% of the BP reduction of the standard dose (0.25 mg) when all doses were combined with chlorthalidone 25 or 50 mg.[25]

The study by Liao, et al.[15] claimed that reserpine use is a risk factor of depression (OR = 6.667, 95% CI: 1.981–22.43) in hypertensive patients. However, in their study, the dosage of reserpine was not reported; furthermore, we found the some of the data presented in this report is hard to explain after careful examination.

We believe the results of our study have important clinical implications. Both hypertension and depression are leading contributors to the global disease burden in China. Considering that millions of Chinese hypertensive patients are taking reserpine-containing compounds as their treatment medication, if there do exist an association between reserpine use and the development of depression or depres-

| Table 2. Depression status in reserpine users and non-reserpine users. |
|---------------------------------------------------------------|
| **Reserpine user (n = 787)** | **Non-reserpine user (n = 787)** | **P-value** |
|---------------------------------|---------------------------------|-------------|
| Zung depression score | 40.4 ± 10.8 | 40.6 ± 10.7 | 0.70 |
| Depression classification | | | |
| No | 689 (87.6%) | 694 (88.2%) | 0.86 |
| Mild | 74 (9.4%) | 67 (8.5%) | 0.56 |
| Moderate | 19 (2.4%) | 25 (3.2%) | 0.34 |
| Severe | 5 (0.6%) | 1 (0.1%) | 0.12 |

Data are presented as means ± SD or n (%).

| Table 3. Depression status in patients 80 years or older. |
|---------------------------------------------------------------|
| **Reserpine user (n = 102)** | **Non-reserpine user (n = 84)** | **P-value** |
|---------------------------------|---------------------------------|-------------|
| Zung depression score | 40.0 ± 12.3 | 41.5 ± 11.0 | 0.399 |
| Depression classification | | | |
| No | 87 (85.3%) | 70 (83.3%) | 0.89 |
| Mild | 9 (8.8%) | 9 (10.7%) | 0.46 |
| Moderate | 4 (3.9%) | 5 (6.0%) | 0.54 |
| Severe | 2 (2.0%) | 0 | 0.34 |

Data are presented as means ± SD or n (%).
sive symptoms, the use of reserpine as anti-hypertension drug should be discouraged. On the contrary, because reserpine is a very effective antihypertensive agent, especially when used as part of a 2- or 3-drug regimen and has outcomes data attesting to its effectiveness,\textsuperscript{[4–7,8,16]} and compared to other classes of anti-hypertensive medications, reserpine is relatively cheap and has a very long duration of action (days) and may therefore be helpful to enhance patient adherence, then the role of reserpine as an antihypertensive agent should be reconsidered, particularly in economically developing countries and areas such as China.

4.1 Limitations

The major limitation of our study is the nature of cross-sectional design. Another important limitation of our study is that we used a self-rating scale to assess depression status which may overestimate or underestimate depression prevalence in hypertensive patients.\textsuperscript{[20]} However, the prevalence of depression and the mean depressive score in our studied subjects are comparable to those results of most studies on the prevalence of depression in patients with hypertension.\textsuperscript{[27]}

4.2 Conclusions

In conclusion, our present study shows that there is no association between low-dose reserpine use and depression in older hypertensive patient. This result, combined with other recent studies on the safety and tolerability of low dose reserpine as an anti-hypertension medication, strongly suggest that the role of reserpine in the treatment and control of hypertension should be reconsidered, and further studies, especially randomized, controlled clinical trials to compare efficacy and safety of reserpine and other widely recommended anti-hypertensive agents are needed.

Acknowledgments

All authors had no conflicts of interest to disclose.

References

1 Mashour NH, Lin GI, Frishman WH. Herbal medicine for the treatment of cardiovascular disease: clinical considerations. \textit{Arch Intern Med} 1998; 158: 2225–2234.

2 Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. \textit{JAMA} 1967; 202: 1028–1034.

3 Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. \textit{JAMA} 1970; 213: 1143–1152.

4 Finnerty FA Jr, Gytoypoulos A, Berry C, et al. Step 2 regimens in hypertension. An assessment. \textit{JAMA} 1979; 241: 579–581.

5 Griebenow R, Pittrow DB, Weidinger G, et al. Low-dose reserpine/thiazide combination in first-line treatment of hypertension: efficacy and safety compared to an ACE inhibitor. \textit{Blood Press} 1997; 6: 299–306.

6 Kostis JB, Berge KG, Davis BR, et al. Effects of atenolol and reserpine on selected events in the Systolic Hypertension in the elderly Program (SHEP). \textit{J Am Hypertens} 1995; 8: 1147–1153.

7 Kröning B, Pittrow DB, Kirch W, et al. Different concepts in first-line treatment of essential hypertension. Comparison of a low-dose reserpine-thiazide combination with nitrendipine monotherapy. \textit{Hypertension} 1997; 29: 651–658.

8 Major outcomes in high-risk hypertensive patients randomized to angiotension-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALL-HAT). \textit{JAMA} 2002; 288: 2981–2997.

9 Slim HB, Black HR, Thompson PD. Older blood pressure medications-do they still have a place? \textit{Am J Cardiol} 2011; 108: 308–316.

10 Sheng CS, Liu M, Kang YY, et al. Prevalence, awareness, treatment and control of hypertension in elderly Chinese. \textit{Hypertens Res} 2013; 36: 824–828.

11 Wang Z, Chen Z, Zhang L, et al. Status of hypertension in China: results from the China hypertension survey, 2012-2015. \textit{Circulation} 2018; 137: 2344–2356.

12 Lu J, Lu Y, Wang X, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project). \textit{Lancet} 2017; 390: 2549–2558.

13 Curb JD, Hardy RJ, Labarthe DR, et al. Reserpine and breast cancer in the Hypertension Detection and Follow-Up Program. \textit{Hypertension} 1982; 4: 307–311.

14 Shorr RI, Ray WA, Daughtrey JR, et al. Reserpine reconsidered: no association with serious peptic ulcer disease. \textit{J Gen Intern Med} 1993; 8: 510–512.

15 Liao J, Wang X, Liu C, et al. Prevalence and related risk factors of hypertensive patients with co-morbid anxiety and/or depression in community: a cross-sectional study. \textit{Zhonghua Yi Xue Za Zhi} 2014; 94: 62–66. [In Chinese].

16 Wu Y, Hu Y, Tang X, et al. Long-term efficacy and tolerability of a fixed-dose combination of antihypertensive agents: an open-label surveillance study in China. \textit{Clin Drug Investig} 2011; 31: 769–777.

17 Zung WW. A self-rating depression scale. \textit{Arch Gen Psychiatry} 1965; 12: 63–70.

18 Shen M, Hu M, Sun Z. Development and validation of brief scales to measure emotional and behavioral problems among Chinese adolescents. \textit{BMJ Open} 2017; 7: e012961–e012961.

19 Lee HC, Chiu HF, Wing YK, et al. The Zung Self-rating Depression Scale: screening for depression among the Hong Kong Chinese elderly. \textit{J Geriatr Psychiatry Neurol} 1994; 7: 216–220.
20 Mingyuan Zhang. References. In The Manual of psychiatric rating scale. [In Chinese]. Eds.; Hunan Science and Technology Press: Hunan, China, 1993; Volume 1, 258–258.
21 Lemieux G, Davignon A, Genest J. Depressive states during Rauwolfia therapy for arterial hypertension: a report of 30 cases. Can Med Assoc J 1956; 74: 522–526.
22 Maharaj B, van der Byl K. Randomised double-blind comparative study of efficacy and safety of hydroflumethiazide and reserpine and chlorthalidone and atenolol in the treatment of mild to moderate hypertension in black patients. J Hum Hypertens 1993; 7: 447–450.
23 Goldstein G, Materson BJ, Cushman WC, et al. Treatment of hypertension in the elderly: II. Cognition and behavioral function. Results of a department of Veterans Affairs cooperative study. Hypertension 1990; 15: 361–369.
24 Shamon SD, Perez MI. Blood pressure-lowering efficacy of reserpine for primary hypertension. Cochrane Database Syst Rev 2016; 12: CD007655–CD007655.
25 Participating Veterans Administration Medical Centers. Major outcomes in high-risk hypertensive patients randomized to Low doses v standard dose of reserpine. A randomized, double-blind, multiclinic trial in patients taking chlorthalidone. JAMA 1982; 248: 2471–2477.
26 Hedayati SS, Bosworth HB, Kuchibhatla M, et al. The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients. Kidney Int 2006; 69: 1662–1668.
27 Li Z, Li Y, Chen L, et al. Prevalence of depression in patients with hypertension: a systematic review and meta-analysis. Medicine (Baltimore) 2015; 94: e1317–e1317.